Search results for "FIBROSIS"

showing 10 items of 901 documents

Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system

2019

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.2 Myelofibrosis diagnosis relies upon the evaluation of several clinical and laboratory criteria suggested by the World Health Organization (WHO) in 2016.3 The major mutations leading to myelofibrosis usually occur in the JAK2, CALR, and MPL genes. However, in almost 10% of the cases, none of the above-mentioned mutations can be detected …

PharmacologyCytopeniamedicine.medical_specialtyRuxolitinibbusiness.industryIPSSruxolitinibprimary myelofibrosilcsh:RM1-950Case ReportGeneral Medicinemedicine.diseaseDiscontinuationPolycythemia veralcsh:Therapeutics. PharmacologyInternational Prognostic Scoring SystemInternal medicinemedicineprimary myelofibrosisMolecular MedicineMyelofibrosisAdverse effectbusinessMyeloproliferative neoplasmmedicine.drugDrugs in Context
researchProduct

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis

2022

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis within the alveolar wall that are not due to infection or cancer. Oxidative stress has been proposed as a key molecular process in pulmonary fibrosis development and different components of the redox system are altered in the cellular actors participating in lung fibrosis. To this respect, several activators of the antioxidant machinery and inhibitors of the oxidant species and pathways have been assayed in preclinicalin vitroandin vivomodels and in different clinical trials. This review discusses the role of …

PharmacologyIPF—idiopathic pulmonary fibrosisantioxidant therapyfibrosisoxidative stressPharmacology (medical)Therapeutics. PharmacologyRM1-950Reviewrespiratory systemROS—reactive oxygen speciesrespiratory tract diseasesFrontiers in Pharmacology
researchProduct

Nonsense codons suppression. An acute toxicity study of three optimized TRIDs in murine model, safety and tolerability evaluation.

2022

Stop mutations cause 11% of the genetic diseases, due to the introduction of a premature termination codon (PTC) in the mRNA, followed by the production of a truncated protein. A promising therapeutic approach is the suppression therapy by Translational Readthrough Inducing Drugs (TRIDs), restoring the expression of the protein. Recently, three new TRIDs (NV848, NV914, NV930) have been proposed, and validated by several in vitro assays, for the rescue of the CFTR protein, involved in Cystic Fibrosis disease. In this work, an acute toxicological study for the three TRIDs was conducted in vivo on mice, according to the OECD No.420 guidelines. Animals were divided into groups and treated with …

PharmacologyNonsense mutationCystic Fibrosis Transmembrane Conductance RegulatorGeneral MedicineOxadiazoleMiceDisease Models AnimalPremature termination codon (PTC)Pharmaceutical PreparationsCodon NonsenseProtein BiosynthesisAnimalsToxicity studyTranslational readthrough inducing drugs(TRIDs)Biomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats

2003

1. This study examines the activity of the antioxidant N-acetylcysteine on bleomycin-induced pulmonary fibrosis in rats with emphasis on the early inflammatory phase. 2. Rats receiving N-acetylcysteine (300 mg kg(-1) day(-1), intraperitoneal) had less augmented lung wet weight, and lower levels of proteins, lactate dehydrogenase, neutrophil and macrophage counts in bronchoalveolar lavage fluid and lung myeloperoxidase activity with a betterment of histological score at 3 days postbleomycin. 3. A diminished lung GSH/GSSG ratio and augmented lipid hydroperoxides were observed 3 days postbleomycin. These changes were attenuated by N-acetylcysteine. Alveolar macrophages from bleomycin-exposed r…

PharmacologyPathologymedicine.medical_specialtyNecrosisLungmedicine.diagnostic_testbusiness.industrySuperoxiderespiratory systemmedicine.diseaseBleomycinrespiratory tract diseasesNitric oxideDrug vehiclechemistry.chemical_compoundBronchoalveolar lavageEndocrinologymedicine.anatomical_structurechemistryInternal medicinePulmonary fibrosismedicinemedicine.symptombusinessBritish Journal of Pharmacology
researchProduct

Strategies targeting fibrosis in pulmonary disease

2006

Pulmonary fibrosis is potentially a curable disease, but this potential is dependent on correct identification of disease targets at the research stage. While invaluable work has been done in animal models to identify factors involved in the initiation of fibrogenesis, we must now shift our focus towards identifying factors involved in the chronic progression of fibrosis and how to modulate the progressive nature of the disease towards repair or regeneration of non-functioning pulmonary tissue.

PharmacologyPathologymedicine.medical_specialtybusiness.industryRegeneration (biology)Pulmonary diseaseDiseasemedicine.diseaseBioinformaticsFibrosisDrug DiscoveryPulmonary fibrosismedicineMolecular MedicinebusinessDrug Discovery Today: Therapeutic Strategies
researchProduct

Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mielo…

2016

Abstract Introduction: Patients with Philadelphia-negative chronic myeloproliferative neoplasms (Ph-MPN), polycytemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), are prone to develop thrombotic events. We aimed to investigate the coagulation status in their plasma using thrombin generation assay (TGA), a functional global assay, on Ceveron® Alpha. Materials and methods: The samples were collected from 89 consecutive Ph-negative MPN patients and from 78 controls into K2EDTA and CTAD tubes for blood cell counts, TGA and coagulation screening tests. Thrombin generation was analysed in platelet-poor plasma using Technothrombin® TGA assay kit. Results: We found a …

Philadelphia negativeessential thrombocythemiaidiopatic myelofibrosisbusiness.industryR030204 cardiovascular system & hematologyThrombin generation03 medical and health sciences0302 clinical medicinepolycythemia verahemic and lymphatic diseasesthrombin generationCancer researchMedicineMedicinebusinessthrombosis030215 immunologyRomanian Journal of Laboratory Medicine
researchProduct

Machine Learning Identification of Pro-arrhythmic Structures in Cardiac Fibrosis

2021

Cardiac fibrosis and other scarring of the heart, arising from conditions ranging from myocardial infarction to ageing, promotes dangerous arrhythmias by blocking the healthy propagation of cardiac excitation. Owing to the complexity of the dynamics of electrical signalling in the heart, however, the connection between different arrangements of blockage and various arrhythmic consequences remains poorly understood. Where a mechanism defies traditional understanding, machine learning can be invaluable for enabling accurate prediction of quantities of interest (measures of arrhythmic risk) in terms of predictor variables (such as the arrangement or pattern of obstructive scarring). In this st…

PhysiologyCardiac fibrosisStimulus (physiology)arrhythmiaMachine learningcomputer.software_genreunidirectional blockFibrosisPhysiology (medical)QP1-981MedicineMyocardial infarctionOriginal ResearchArtificial neural networkbusiness.industryCardiac electrophysiologyMechanism (biology)fibrosisneural networksmedicine.diseaseIdentification (information)machine learningmonodomain modelre-entryArtificial intelligencebusinesscardiac electrophysiologycomputerFrontiers in Physiology
researchProduct

Fgf9 Prevents Pleural Fibrosis Induced By Intra-Pleural Adenovirus Injection In Mice

2017

International audience

Pleural Fibrosis[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractComputingMilieux_MISCELLANEOUSAntifibrotic effect
researchProduct

PEGYLATED POLYASPARTAMIDE–POLYLACTIDE BASED NANOPARTICLES PENETRATING CYSTIC FIBROSIS ARTIFICIAL MUCUS

2016

Here, the preparation of mucus-penetrating nanoparticles for pulmonary administration of ibuprofen in patients with cystic fibrosis is described. A fluorescent derivative of α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide is synthesized by derivatization with rhodamine, polylactide, and poly(ethylene glycol), to obtain polyaspartamide− polylactide derivatives with different degrees of pegylation. Starting from these copolymers, fluorescent nanoparticles with different poly(ethylene glycol) content, empty and loaded with ibuprofen, showed spherical shape, colloidal size, slightly negative ζ potential, and biocompatibility toward human bronchial epithelial cells. The high surface poly(ethylene gly…

Polymers and PlasticsBiocompatibilityPolyestersαL-aspartamideNanoparticleBioengineeringIbuprofen02 engineering and technologyRespiratory Mucosa010402 general chemistry01 natural sciencesCell LinePolyethylene GlycolsBiomaterialsRhodaminecystic fibrosischemistry.chemical_compoundpolymeric nanoparticles cystic fibrosis αβ-poly(N-2-hydroxyethyl)-DL-aspartamideMaterials ChemistryCopolymerOrganic chemistryHumansDerivatizationβ-poly(N-2-hydroxyethyl)-Dpolymeric nanoparticles; cystic fibrosis; α; β-poly(N-2-hydroxyethyl)-D; L-aspartamide021001 nanoscience & nanotechnologyMucus0104 chemical sciencesMucuspolymeric nanoparticleschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPEGylationNanoparticles0210 nano-technologyPeptidesEthylene glycolNuclear chemistry
researchProduct

α-Mannosyl-Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages

2019

Immunosuppressive M2 macrophages govern the immunophathogenic micromilieu in many severe diseases including cancer or fibrosis, thus, their re-polarization through RNA interference is a promising concept to support combinatorial therapies. For targeted siRNA delivery, however, safe and stable carriers are required that manage cell specific transport to M2 macrophages. Here, siRNA-loaded cationic nanogels are reported with α-mannosyl decorated surfaces that target and modify M2 macrophages selectively. Via amphiphilic precursor block copolymers bearing one single α-mannosyl moiety at their chain end mannosylated cationic nanohydrogel particles (ManNP) were obtained of 20 nm diameter determin…

Polymers and PlasticsCellBioengineering02 engineering and technology010402 general chemistry01 natural sciencesBiomaterialsMiceFibrosisRNA interferenceCationsmedicineMaterials ChemistryAnimalsHumansMannanImmunosuppression TherapyGene knockdownbiologyChemistryMacrophagesHydrogels3T3 CellsHep G2 Cells021001 nanoscience & nanotechnologymedicine.diseaseIn vitro0104 chemical sciencesCell biologymedicine.anatomical_structureRAW 264.7 CellsConcanavalin AGene Knockdown Techniquesbiology.proteinNanoparticles0210 nano-technologyMannoseMannose receptorBiotechnologyMacromolecular Bioscience
researchProduct